Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2024 02:00 ET | Source: AAVantgarde Bio

AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024

AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa USH1B
September 16, 2024 02:00 ET | Source: AAVantgarde Bio

AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B

AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study
May 03, 2024 03:00 ET | Source: AAVantgarde Bio

AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B

AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B